{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T19:46:36Z","timestamp":1795203996605,"version":"4.10.3"},"reference-count":155,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T00:00:00Z","timestamp":1625011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T00:00:00Z","timestamp":1625011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The Philadelphia negative myeloproliferative neoplasms (MPN) compromise a heterogeneous group of clonal myeloid stem cell disorders comprising polycythaemia vera, essential thrombocythaemia and primary myelofibrosis. Despite distinct clinical entities, these disorders are linked by morphological similarities and propensity to thrombotic complications and leukaemic transformation. Current therapeutic options are limited in disease-modifying activity with a focus on the prevention of thrombus formation. Constitutive activation of the JAK\/STAT signalling pathway is a hallmark of pathogenesis across the disease spectrum with driving mutations in\n                    <jats:italic>JAK2<\/jats:italic>\n                    ,\n                    <jats:italic>CALR<\/jats:italic>\n                    and\n                    <jats:italic>MPL<\/jats:italic>\n                    identified in the majority of patients. Co-occurring somatic mutations in genes associated with epigenetic regulation, transcriptional control and splicing of RNA are variably but recurrently identified across the MPN disease spectrum, whilst epigenetic contributors to disease are increasingly recognised. The prognostic implications of one MPN diagnosis may significantly limit life expectancy, whilst another may have limited impact depending on the disease phenotype, genotype and other external factors. The genetic and clinical similarities and differences in these disorders have provided a unique opportunity to understand the relative contributions to MPN, myeloid and cancer biology generally from specific genetic and epigenetic changes. This review provides a comprehensive overview of the molecular pathophysiology of MPN exploring the role of driver mutations, co-occurring mutations, dysregulation of intrinsic cell signalling, epigenetic regulation and genetic predisposing factors highlighting important areas for future consideration.\n                  <\/jats:p>","DOI":"10.1186\/s13045-021-01116-z","type":"journal-article","created":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T09:02:56Z","timestamp":1625043776000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":117,"title":["Molecular pathogenesis of the myeloproliferative neoplasms"],"prefix":"10.1186","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2333-1374","authenticated-orcid":false,"given":"Graeme","family":"Greenfield","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Frances","family":"McMullin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Mills","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,30]]},"reference":[{"issue":"20","key":"1116_CR1","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391\u2013405.","journal-title":"Blood"},{"issue":"22","key":"1116_CR2","doi-asserted-by":"publisher","first-page":"e123","DOI":"10.1182\/blood-2014-02-554634","volume":"123","author":"R Rampal","year":"2014","unstructured":"Rampal R, Al-Shahrour F, Abdel-Wahab O, Patel JP, Brunel JP, Mermel CH, et al. Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis. Blood. 2014;123(22):e123\u201333.","journal-title":"Blood"},{"issue":"4","key":"1116_CR3","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","volume":"7","author":"RL Levine","year":"2005","unstructured":"Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7(4):387\u201397.","journal-title":"Cancer Cell"},{"issue":"5","key":"1116_CR4","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1056\/NEJMoa065202","volume":"356","author":"LM Scott","year":"2007","unstructured":"Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med. 2007;356(5):459\u201368.","journal-title":"N Engl J Med"},{"issue":"9464","key":"1116_CR5","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","volume":"365","author":"EJ Baxter","year":"2005","unstructured":"Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365(9464):1054\u201361.","journal-title":"Lancet"},{"issue":"17","key":"1116_CR6","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1056\/NEJMoa051113","volume":"352","author":"R Kralovics","year":"2005","unstructured":"Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779\u201390.","journal-title":"N Engl J Med"},{"issue":"25","key":"1116_CR7","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","volume":"369","author":"J Nangalia","year":"2013","unstructured":"Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013;369(25):2391\u2013405.","journal-title":"N Engl J Med"},{"issue":"7","key":"1116_CR8","doi-asserted-by":"publisher","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","volume":"3","author":"Y Pikman","year":"2006","unstructured":"Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006;3(7):e270.","journal-title":"PLoS Med."},{"issue":"23","key":"1116_CR9","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1182\/blood-2017-06-782037","volume":"130","author":"J Nangalia","year":"2017","unstructured":"Nangalia J, Green AR. Myeloproliferative neoplasms: from origins to outcomes. Blood. 2017;130(23):2475\u201383.","journal-title":"Blood"},{"issue":"2","key":"1116_CR10","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41408-018-0054-y","volume":"8","author":"T Barbui","year":"2018","unstructured":"Barbui T, Thiele J, Gisslinger H, Kvasnicka HM, Vannucchi AM, Guglielmelli P, et al. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer J. 2018;8(2):15.","journal-title":"Blood Cancer J"},{"issue":"12","key":"1116_CR11","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1016\/j.leukres.2012.08.013","volume":"36","author":"J Mascarenhas","year":"2012","unstructured":"Mascarenhas J, Heaney ML, Najfeld V, Hexner E, Abdel-Wahab O, Rampal R, et al. Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium. Leuk Res. 2012;36(12):1500\u20134.","journal-title":"Leuk Res"},{"issue":"2","key":"1116_CR12","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1111\/bjh.15648","volume":"184","author":"MF McMullin","year":"2019","unstructured":"McMullin MF, Harrison CN, Ali S, Cargo C, Chen F, Ewing J, et al. A guideline for the diagnosis and management of polycythaemia vera. A British Society for Haematology Guideline. Br J Haematol. 2019;184(2):176\u201391.","journal-title":"Br J Haematol."},{"issue":"2","key":"1116_CR13","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1182\/bloodadvances.2016000208","volume":"1","author":"A Tefferi","year":"2016","unstructured":"Tefferi A, Lasho TL, Finke CM, Elala Y, Hanson CA, Ketterling RP, et al. Targeted deep sequencing in primary myelofibrosis. Blood Adv. 2016;1(2):105\u201311.","journal-title":"Blood Adv"},{"issue":"1","key":"1116_CR14","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1182\/bloodadvances.2016000216","volume":"1","author":"A Tefferi","year":"2016","unstructured":"Tefferi A, Lasho TL, Guglielmelli P, Finke CM, Rotunno G, Elala Y, et al. Targeted deep sequencing in polycythemia vera and essential thrombocythemia. Blood Adv. 2016;1(1):21\u201330.","journal-title":"Blood Adv"},{"issue":"15","key":"1116_CR15","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1056\/NEJMoa1716614","volume":"379","author":"J Grinfeld","year":"2018","unstructured":"Grinfeld J, Nangalia J, Baxter EJ, Wedge DC, Angelopoulos N, Cantrill R, et al. Classification and personalized prognosis in myeloproliferative neoplasms. N Engl J Med. 2018;379(15):1416\u201330.","journal-title":"N Engl J Med"},{"issue":"6","key":"1116_CR16","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1016\/j.molcel.2019.01.009","volume":"73","author":"A Rodriguez-Meira","year":"2019","unstructured":"Rodriguez-Meira A, Buck G, Clark SA, Povinelli BJ, Alcolea V, Louka E, et al. Unravelling intratumoral heterogeneity through high-sensitivity single-cell mutational analysis and parallel RNA sequencing. Mol Cell. 2019;73(6):1292-305.e8.","journal-title":"Mol Cell"},{"issue":"23","key":"1116_CR17","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209\u201321.","journal-title":"N Engl J Med"},{"issue":"3","key":"1116_CR18","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s12185-014-1670-3","volume":"101","author":"K Zoi","year":"2015","unstructured":"Zoi K, Cross NC. Molecular pathogenesis of atypical CML, CMML and MDS\/MPN-unclassifiable. Int J Hematol. 2015;101(3):229\u201342.","journal-title":"Int J Hematol"},{"issue":"26","key":"1116_CR19","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","volume":"371","author":"S Jaiswal","year":"2014","unstructured":"Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371(26):2488\u201398.","journal-title":"N Engl J Med"},{"issue":"2","key":"1116_CR20","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1701719","volume":"377","author":"S Jaiswal","year":"2017","unstructured":"Jaiswal S, Natarajan P, Silver AJ, Gibson CJ, Bick AG, Shvartz E, et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med. 2017;377(2):111\u201321.","journal-title":"N Engl J Med"},{"issue":"3","key":"1116_CR21","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/s41569-019-0247-5","volume":"17","author":"S Jaiswal","year":"2020","unstructured":"Jaiswal S, Libby P. Clonal haematopoiesis: connecting ageing and inflammation in cardiovascular disease. Nat Rev Cardiol. 2020;17(3):137\u201344.","journal-title":"Nat Rev Cardiol"},{"issue":"2","key":"1116_CR22","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1056\/NEJMoa035572","volume":"350","author":"R Landolfi","year":"2004","unstructured":"Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med. 2004;350(2):114\u201324.","journal-title":"N Engl J Med"},{"key":"1116_CR23","doi-asserted-by":"publisher","first-page":"794240","DOI":"10.1155\/2011\/794240","volume":"2011","author":"R Marchioli","year":"2011","unstructured":"Marchioli R, Finazzi G, Specchia G, Masciulli A, Mennitto MR, Barbui T. The CYTO-PV: a large-scale trial testing the intensity of CYTOreductive therapy to prevent cardiovascular events in patients with polycythemia vera. Thrombosis. 2011;2011:794240.","journal-title":"Thrombosis"},{"issue":"3","key":"1116_CR24","doi-asserted-by":"publisher","first-page":"e196","DOI":"10.1016\/S2352-3026(19)30236-4","volume":"7","author":"H Gisslinger","year":"2020","unstructured":"Gisslinger H, Klade C, Georgiev P, Krochmalczyk D, Gercheva-Kyuchukova L, Egyed M, et al. Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study. Lancet Haematol. 2020;7(3):e196\u2013208.","journal-title":"Lancet Haematol"},{"issue":"8","key":"1116_CR25","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1038\/leu.2016.148","volume":"30","author":"CN Harrison","year":"2016","unstructured":"Harrison CN, Vannucchi AM, Kiladjian JJ, Al-Ali HK, Gisslinger H, Knoops L, et al. Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia. 2016;30(8):1701\u20137.","journal-title":"Leukemia"},{"key":"1116_CR26","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1007\/s00277-018-3365-y","volume":"97","author":"M Griesshammer","year":"2018","unstructured":"Griesshammer M, Saydam G, Palandri F, Benevolo G, Egyed M, Callum J, et al. Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial. Ann Hematol. 2018;97:1591\u2013600.","journal-title":"Ann Hematol"},{"issue":"9","key":"1116_CR27","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1110557","volume":"366","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(9):799\u2013807.","journal-title":"N Engl J Med"},{"issue":"5","key":"1116_CR28","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1056\/NEJMoa1409002","volume":"372","author":"AM Vannucchi","year":"2015","unstructured":"Vannucchi AM, Kiladjian JJ, Griesshammer M, Masszi T, Durrant S, Passamonti F, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015;372(5):426\u201335.","journal-title":"N Engl J Med"},{"issue":"9","key":"1116_CR29","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1016\/j.bbmt.2017.05.007","volume":"23","author":"T Jain","year":"2017","unstructured":"Jain T, Mesa RA, Palmer JM. Allogeneic stem cell transplantation in myelofibrosis. Biol Blood Marrow Transplant. 2017;23(9):1429\u201336.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"21","key":"1116_CR30","doi-asserted-by":"publisher","first-page":"5562","DOI":"10.1182\/bloodadvances.2020002727","volume":"4","author":"V Gupta","year":"2020","unstructured":"Gupta V, Kennedy JA, Capo-Chichi JM, Kim S, Hu ZH, Alyea EP, et al. Genetic factors rather than blast reduction determine outcomes of allogeneic HCT in BCR-ABL-negative MPN in blast phase. Blood Adv. 2020;4(21):5562\u201373.","journal-title":"Blood Adv"},{"issue":"2","key":"1116_CR31","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1124\/pr.119.018440","volume":"72","author":"U Bharadwaj","year":"2020","unstructured":"Bharadwaj U, Kasembeli MM, Robinson P, Tweardy DJ. Targeting Janus kinases and signal transducer and activator of transcription 3 to treat inflammation, fibrosis, and cancer: rationale, progress, and caution. Pharmacol Rev. 2020;72(2):486\u2013526.","journal-title":"Pharmacol Rev"},{"issue":"8","key":"1116_CR32","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1038\/s41375-018-0117-x","volume":"32","author":"B Wingelhofer","year":"2018","unstructured":"Wingelhofer B, Neubauer HA, Valent P, Han X, Constantinescu SN, Gunning PT, et al. Implications of STAT3 and STAT5 signaling on gene regulation and chromatin remodeling in hematopoietic cancer. Leukemia. 2018;32(8):1713\u201326.","journal-title":"Leukemia"},{"issue":"22","key":"1116_CR33","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1182\/blood-2017-11-814913","volume":"131","author":"E Tiacci","year":"2018","unstructured":"Tiacci E, Ladewig E, Schiavoni G, Penson A, Fortini E, Pettirossi V, et al. Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma. Blood. 2018;131(22):2454\u201365.","journal-title":"Blood"},{"issue":"8","key":"1116_CR34","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1038\/ng.3909","volume":"49","author":"Y Liu","year":"2017","unstructured":"Liu Y, Easton J, Shao Y, Maciaszek J, Wang Z, Wilkinson MR, et al. The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia. Nat Genet. 2017;49(8):1211\u20138.","journal-title":"Nat Genet"},{"key":"1116_CR35","doi-asserted-by":"publisher","first-page":"100634","DOI":"10.1016\/j.blre.2019.100634","volume":"40","author":"S Venugopal","year":"2020","unstructured":"Venugopal S, Bar-Natan M, Mascarenhas JO. JAKs to STATs: a tantalizing therapeutic target in acute myeloid leukemia. Blood Rev. 2020;40:100634.","journal-title":"Blood Rev."},{"issue":"2","key":"1116_CR36","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nrc1275","volume":"4","author":"H Yu","year":"2004","unstructured":"Yu H, Jove R. The STATs of cancer\u2014new molecular targets come of age. Nat Rev Cancer. 2004;4(2):97\u2013105.","journal-title":"Nat Rev Cancer"},{"issue":"7037","key":"1116_CR37","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1038\/nature03546","volume":"434","author":"C James","year":"2005","unstructured":"James C, Ugo V, Le Cou\u00e9dic JP, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434(7037):1144\u20138.","journal-title":"Nature"},{"issue":"1","key":"1116_CR38","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1186\/s12885-019-5764-4","volume":"19","author":"M Mejia-Ochoa","year":"2019","unstructured":"Mejia-Ochoa M, Acevedo Toro PA, Cardona-Arias JA. Systematization of analytical studies of polycythemia vera, essential thrombocythemia and primary myelofibrosis, and a meta-analysis of the frequency of JAK2, CALR and MPL mutations: 2000\u20132018. BMC Cancer. 2019;19(1):590.","journal-title":"BMC Cancer"},{"issue":"15","key":"1116_CR39","doi-asserted-by":"publisher","first-page":"3325","DOI":"10.1182\/blood-2008-04-149047","volume":"114","author":"J Ding","year":"2009","unstructured":"Ding J, Komatsu H, Iida S, Yano H, Kusumoto S, Inagaki A, et al. The Asn505 mutation of the c-MPL gene, which causes familial essential thrombocythemia, induces autonomous homodimerization of the c-Mpl protein due to strong amino acid polarity. Blood. 2009;114(15):3325\u20138.","journal-title":"Blood"},{"issue":"5","key":"1116_CR40","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1038\/leu.2015.271","volume":"30","author":"JP Defour","year":"2016","unstructured":"Defour JP, Chachoua I, Pecquet C, Constantinescu SN. Oncogenic activation of MPL\/thrombopoietin receptor by 17 mutations at W515: implications for myeloproliferative neoplasms. Leukemia. 2016;30(5):1214\u20136.","journal-title":"Leukemia"},{"issue":"4","key":"1116_CR41","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1182\/blood.2019002561","volume":"135","author":"JL Bridgford","year":"2020","unstructured":"Bridgford JL, Lee SM, Lee CMM, Guglielmelli P, Rumi E, Pietra D, et al. Novel drivers and modifiers of MPL-dependent oncogenic transformation identified by deep mutational scanning. Blood. 2020;135(4):287\u201392.","journal-title":"Blood"},{"issue":"25","key":"1116_CR42","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1182\/blood.2019000622","volume":"134","author":"J How","year":"2019","unstructured":"How J, Hobbs GS, Mullally A. Mutant calreticulin in myeloproliferative neoplasms. Blood. 2019;134(25):2242\u20138.","journal-title":"Blood"},{"issue":"1","key":"1116_CR43","doi-asserted-by":"publisher","first-page":"4886","DOI":"10.1038\/s41467-020-18691-3","volume":"11","author":"C Benlabiod","year":"2020","unstructured":"Benlabiod C, Cacemiro MDC, Nedelec A, Edmond V, Muller D, Rameau P, et al. Calreticulin del52 and ins5 knock-in mice recapitulate different myeloproliferative phenotypes observed in patients with MPN. Nat Commun. 2020;11(1):4886.","journal-title":"Nat Commun"},{"key":"1116_CR44","doi-asserted-by":"crossref","unstructured":"Michail O, McCallion P, McGimpsey J, Hindley A, Greenfield G, Feerick J, et al. Mutational profiling in suspected triple-negative essential thrombocythaemia using targeted next-generation sequencing in a real-world cohort. J Clin Pathol. 2020;jclinpath-2020-206570.","DOI":"10.1136\/jclinpath-2020-206570"},{"issue":"5","key":"1116_CR45","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/j.hoc.2012.07.007","volume":"26","author":"A Mullally","year":"2012","unstructured":"Mullally A, Lane SW, Brumme K, Ebert BL. Myeloproliferative neoplasm animal models. Hematol Oncol Clin N Am. 2012;26(5):1065\u201381.","journal-title":"Hematol Oncol Clin N Am"},{"issue":"4","key":"1116_CR46","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1111\/bjh.12274","volume":"161","author":"S Verstovsek","year":"2013","unstructured":"Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, et al. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis. Br J Haematol. 2013;161(4):508\u201316.","journal-title":"Br J Haematol"},{"issue":"1","key":"1116_CR47","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3324\/haematol.11653","volume":"93","author":"E Antonioli","year":"2008","unstructured":"Antonioli E, Guglielmelli P, Poli G, Bogani C, Pancrazzi A, Longo G, et al. Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia. Haematologica. 2008;93(1):41\u20138.","journal-title":"Haematologica"},{"issue":"5","key":"1116_CR48","doi-asserted-by":"publisher","first-page":"718","DOI":"10.3324\/haematol.2012.079129","volume":"98","author":"AL Godfrey","year":"2013","unstructured":"Godfrey AL, Chen E, Pagano F, Silber Y, Campbell PJ, Green AR. Clonal analyses reveal associations of JAK2V617F homozygosity with hematologic features, age and gender in polycythemia vera and essential thrombocythemia. Haematologica. 2013;98(5):718\u201321.","journal-title":"Haematologica"},{"issue":"9","key":"1116_CR49","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1038\/leu.2010.148","volume":"24","author":"F Passamonti","year":"2010","unstructured":"Passamonti F, Rumi E, Pietra D, Elena C, Boveri E, Arcaini L, et al. A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia. 2010;24(9):1574\u20139.","journal-title":"Leukemia"},{"issue":"2","key":"1116_CR50","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1111\/bjh.14958","volume":"183","author":"J How","year":"2018","unstructured":"How J, Trinkaus KM, Oh ST. Distinct clinical, laboratory and molecular features of myeloproliferative neoplasm patients with splanchnic vein thrombosis. Br J Haematol. 2018;183(2):310\u20133.","journal-title":"Br J Haematol"},{"issue":"10","key":"1116_CR51","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1182\/blood-2013-11-539098","volume":"123","author":"E Rumi","year":"2014","unstructured":"Rumi E, Pietra D, Ferretti V, Klampfl T, Harutyunyan AS, Milosevic JD, et al. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood. 2014;123(10):1544\u201351.","journal-title":"Blood"},{"issue":"4","key":"1116_CR52","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1182\/blood-2012-07-440487","volume":"121","author":"M De Grandis","year":"2013","unstructured":"De Grandis M, Cambot M, Wautier MP, Cassinat B, Chomienne C, Colin Y, et al. JAK2V617F activates Lu\/BCAM-mediated red cell adhesion in polycythemia vera through an EpoR-independent Rap1\/Akt pathway. Blood. 2013;121(4):658\u201365.","journal-title":"Blood"},{"issue":"436","key":"1116_CR53","doi-asserted-by":"publisher","first-page":"eaan8292","DOI":"10.1126\/scitranslmed.aan8292","volume":"10","author":"O Wolach","year":"2018","unstructured":"Wolach O, Sellar RS, Martinod K, Cherpokova D, McConkey M, Chappell RJ, et al. Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms. Sci Transl Med. 2018;10(436):eaan8292.","journal-title":"Sci Transl Med."},{"issue":"22","key":"1116_CR54","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1182\/blood.2019002943","volume":"136","author":"R Nienhold","year":"2020","unstructured":"Nienhold R, Ashcroft P, Zmajkovic J, Rai S, Rao TN, Drexler B, et al. MPN patients with low mutant JAK2 allele burden show late expansion restricted to erythroid and megakaryocytic lineages. Blood. 2020;136(22):2591\u20135.","journal-title":"Blood"},{"issue":"3","key":"1116_CR55","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.3390\/cancers6031408","volume":"6","author":"HF Zhang","year":"2014","unstructured":"Zhang HF, Lai R. STAT3 in cancer-friend or foe? Cancers (Basel). 2014;6(3):1408\u201340.","journal-title":"Cancers (Basel)"},{"issue":"8","key":"1116_CR56","doi-asserted-by":"publisher","first-page":"5296","DOI":"10.1074\/jbc.M109.040733","volume":"285","author":"M Funakoshi-Tago","year":"2010","unstructured":"Funakoshi-Tago M, Tago K, Abe M, Sonoda Y, Kasahara T. STAT5 activation is critical for the transformation mediated by myeloproliferative disorder-associated JAK2 V617F mutant. J Biol Chem. 2010;285(8):5296\u2013307.","journal-title":"J Biol Chem"},{"issue":"5","key":"1116_CR57","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1182\/blood-2005-10-009514","volume":"108","author":"L Garcon","year":"2006","unstructured":"Garcon L, Rivat C, James C, Lacout C, Camara-Clayette V, Ugo V, et al. Constitutive activation of STAT5 and Bcl-xL overexpression can induce endogenous erythroid colony formation in human primary cells. Blood. 2006;108(5):1551\u20134.","journal-title":"Blood"},{"issue":"5","key":"1116_CR58","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.ccr.2010.10.013","volume":"18","author":"E Chen","year":"2010","unstructured":"Chen E, Beer PA, Godfrey AL, Ortmann CA, Li J, Costa-Pereira AP, et al. Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signaling. Cancer Cell. 2010;18(5):524\u201335.","journal-title":"Cancer Cell"},{"issue":"7836","key":"1116_CR59","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/s41586-020-2968-3","volume":"588","author":"AK Jayavelu","year":"2020","unstructured":"Jayavelu AK, Schnoder TM, Perner F, Herzog C, Meiler A, Krishnamoorthy G, et al. Splicing factor YBX1 mediates persistence of JAK2-mutated neoplasms. Nature. 2020;588(7836):157\u201363.","journal-title":"Nature"},{"issue":"15","key":"1116_CR60","doi-asserted-by":"publisher","first-page":"3550","DOI":"10.1182\/blood-2011-12-397554","volume":"119","author":"C Walz","year":"2012","unstructured":"Walz C, Ahmed W, Lazarides K, Betancur M, Patel N, Hennighausen L, et al. Essential role for Stat5a\/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2(V617F) in mice. Blood. 2012;119(15):3550\u201360.","journal-title":"Blood"},{"issue":"15","key":"1116_CR61","doi-asserted-by":"publisher","first-page":"3539","DOI":"10.1182\/blood-2011-03-345215","volume":"119","author":"D Yan","year":"2012","unstructured":"Yan D, Hutchison RE, Mohi G. Critical requirement for Stat5 in a mouse model of polycythemia vera. Blood. 2012;119(15):3539\u201349.","journal-title":"Blood"},{"issue":"25","key":"1116_CR62","doi-asserted-by":"publisher","first-page":"3943","DOI":"10.1182\/blood-2013-07-514208","volume":"123","author":"A Duek","year":"2014","unstructured":"Duek A, Lundberg P, Shimizu T, Grisouard J, Karow A, Kubovcakova L, et al. Loss of Stat1 decreases megakaryopoiesis and favors erythropoiesis in a JAK2-V617F-driven mouse model of MPNs. Blood. 2014;123(25):3943\u201350.","journal-title":"Blood"},{"key":"1116_CR63","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.ebiom.2017.11.013","volume":"26","author":"II Nitulescu","year":"2017","unstructured":"Nitulescu II, Meyer SC, Wen QJ, Crispino JD, Lemieux ME, Levine RL, et al. Mediator kinase phosphorylation of STAT1 S727 promotes growth of neoplasms with JAK-STAT activation. EBioMedicine. 2017;26:112\u201325.","journal-title":"EBioMedicine"},{"issue":"1","key":"1116_CR64","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.3324\/haematol.2015.128546","volume":"101","author":"AL Godfrey","year":"2016","unstructured":"Godfrey AL, Chen E, Massie CE, Silber Y, Pagano F, Bellosillo B, et al. STAT1 activation in association with JAK2 exon 12 mutations. Haematologica. 2016;101(1):e15\u20139.","journal-title":"Haematologica"},{"issue":"6","key":"1116_CR65","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/S0301-472X(01)00637-3","volume":"29","author":"S Roder","year":"2001","unstructured":"Roder S, Steimle C, Meinhardt G, Pahl HL. STAT3 is constitutively active in some patients with Polycythemia rubra vera. Exp Hematol. 2001;29(6):694\u2013702.","journal-title":"Exp Hematol"},{"issue":"8","key":"1116_CR66","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1111\/j.1600-0463.2011.02754.x","volume":"119","author":"M Risum","year":"2011","unstructured":"Risum M, Madelung A, Bondo H, Bzorek M, Kristensen MH, Stamp IM, et al. The JAK2V617F allele burden and STAT3- and STAT5 phosphorylation in myeloproliferative neoplasms: early prefibrotic myelofibrosis compared with essential thrombocythemia, polycythemia vera and myelofibrosis. APMIS. 2011;119(8):498\u2013504.","journal-title":"APMIS"},{"issue":"429","key":"1116_CR67","doi-asserted-by":"publisher","first-page":"eaam7729","DOI":"10.1126\/scitranslmed.aam7729","volume":"10","author":"A Prestipino","year":"2018","unstructured":"Prestipino A, Emhardt AJ, Aumann K, O\u2019Sullivan D, Gorantla SP, Duquesne S, et al. Oncogenic JAK2(V617F) causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms. Sci Transl Med. 2018;10(429):eaam7729.","journal-title":"Sci Transl Med."},{"key":"1116_CR68","doi-asserted-by":"publisher","first-page":"155059","DOI":"10.1016\/j.cyto.2020.155059","volume":"130","author":"JJ Balic","year":"2020","unstructured":"Balic JJ, White CL, Dawson R, Gough D, McCormack MP, Jenkins BJ. STAT3-driven hematopoiesis and lymphopoiesis abnormalities are dependent on serine phosphorylation. Cytokine. 2020;130:155059.","journal-title":"Cytokine."},{"issue":"13","key":"1116_CR69","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1182\/blood-2014-08-594572","volume":"125","author":"J Grisouard","year":"2015","unstructured":"Grisouard J, Shimizu T, Duek A, Kubovcakova L, Hao-Shen H, Dirnhofer S, et al. Deletion of Stat3 in hematopoietic cells enhances thrombocytosis and shortens survival in a JAK2-V617F mouse model of MPN. Blood. 2015;125(13):2131\u201340.","journal-title":"Blood"},{"key":"1116_CR70","first-page":"227","volume":"7","author":"F Comoglio","year":"2018","unstructured":"Comoglio F, Park HJ, Schoenfelder S, Barozzi I, Bode D, Fraser P, et al. Thrombopoietin signaling to chromatin elicits rapid and pervasive epigenome remodeling within poised chromatin architectures. Genome Res. 2018;7:227.","journal-title":"Genome Res."},{"issue":"13","key":"1116_CR71","doi-asserted-by":"publisher","first-page":"3985","DOI":"10.1073\/pnas.1503152112","volume":"112","author":"M Dasgupta","year":"2015","unstructured":"Dasgupta M, Dermawan JK, Willard B, Stark GR. STAT3-driven transcription depends upon the dimethylation of K49 by EZH2. Proc Natl Acad Sci USA. 2015;112(13):3985\u201390.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"1116_CR72","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1038\/leu.2016.280","volume":"31","author":"K Kollmann","year":"2017","unstructured":"Kollmann K, Warsch W, Gonzalez-Arias C, Nice FL, Avezov E, Milburn J, et al. A novel signalling screen demonstrates that CALR mutations activate essential MAPK signalling and facilitate megakaryocyte differentiation. Leukemia. 2017;31(4):934\u201344.","journal-title":"Leukemia"},{"issue":"12","key":"1116_CR73","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/s41408-017-0010-2","volume":"7","author":"R Zini","year":"2017","unstructured":"Zini R, Guglielmelli P, Pietra D, Rumi E, Rossi C, Rontauroli S, et al. CALR mutational status identifies different disease subtypes of essential thrombocythemia showing distinct expression profiles. Blood Cancer J. 2017;7(12):638.","journal-title":"Blood Cancer J"},{"issue":"4","key":"1116_CR74","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1172\/JCI98785","volume":"129","author":"S Stivala","year":"2019","unstructured":"Stivala S, Codilupi T, Brkic S, Baerenwaldt A, Ghosh N, Hao-Shen H, et al. Targeting compensatory MEK\/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms. J Clin Invest. 2019;129(4):1596\u2013611.","journal-title":"J Clin Invest"},{"issue":"57","key":"1116_CR75","doi-asserted-by":"publisher","first-page":"96710","DOI":"10.18632\/oncotarget.18073","volume":"8","author":"N Bartalucci","year":"2017","unstructured":"Bartalucci N, Calabresi L, Balliu M, Martinelli S, Rossi MC, Villeval JL, et al. Inhibitors of the PI3K\/mTOR pathway prevent STAT5 phosphorylation in. Oncotarget. 2017;8(57):96710\u201324.","journal-title":"Oncotarget"},{"issue":"8","key":"1116_CR76","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1182\/blood-2011-01-330563","volume":"118","author":"P Guglielmelli","year":"2011","unstructured":"Guglielmelli P, Barosi G, Rambaldi A, Marchioli R, Masciulli A, Tozzi L, et al. Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1\/2 study in patients with myelofibrosis. Blood. 2011;118(8):2069\u201376.","journal-title":"Blood"},{"issue":"1","key":"1116_CR77","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12943-018-0774-4","volume":"17","author":"S Rocca","year":"2018","unstructured":"Rocca S, Carra G, Poggio P, Morotti A, Brancaccio M. Targeting few to help hundreds: JAK, MAPK and ROCK pathways as druggable targets in atypical chronic myeloid leukemia. Mol Cancer. 2018;17(1):40.","journal-title":"Mol Cancer"},{"issue":"11","key":"1116_CR78","doi-asserted-by":"publisher","first-page":"4924","DOI":"10.1182\/blood-2006-08-039735","volume":"109","author":"MB Hookham","year":"2007","unstructured":"Hookham MB, Elliott J, Suessmuth Y, Staerk J, Ward AC, Vainchenker W, et al. The myeloproliferative disorder-associated JAK2 V617F mutant escapes negative regulation by suppressor of cytokine signaling 3. Blood. 2007;109(11):4924\u20139.","journal-title":"Blood"},{"issue":"2","key":"1116_CR79","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1042\/BJ20131516","volume":"458","author":"LN Varghese","year":"2014","unstructured":"Varghese LN, Ungureanu D, Liau NP, Young SN, Laktyushin A, Hammaren H, et al. Mechanistic insights into activation and SOCS3-mediated inhibition of myeloproliferative neoplasm-associated JAK2 mutants from biochemical and structural analyses. Biochem J. 2014;458(2):395\u2013405.","journal-title":"Biochem J"},{"key":"1116_CR80","doi-asserted-by":"publisher","first-page":"154753","DOI":"10.1016\/j.cyto.2019.154753","volume":"123","author":"M Funakoshi-Tago","year":"2019","unstructured":"Funakoshi-Tago M, Tsuruya R, Ueda F, Ishihara A, Kasahara T, Tamura H, et al. Tyrosine-phosphorylated SOCS3 negatively regulates cellular transformation mediated by the myeloproliferative neoplasm-associated JAK2 V617F mutant. Cytokine. 2019;123:154753.","journal-title":"Cytokine"},{"issue":"11","key":"1116_CR81","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.3324\/haematol.13043","volume":"93","author":"N Fourouclas","year":"2008","unstructured":"Fourouclas N, Li J, Gilby DC, Campbell PJ, Beer PA, Boyd EM, et al. Methylation of the suppressor of cytokine signaling 3 gene (SOCS3) in myeloproliferative disorders. Haematologica. 2008;93(11):1635\u201344.","journal-title":"Haematologica"},{"key":"1116_CR82","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41523-018-0060-z","volume":"4","author":"DG Stover","year":"2018","unstructured":"Stover DG, Gil Del Alcazar CR, Brock J, Guo H, Overmoyer B, Balko J, et al. Phase II study of ruxolitinib, a selective JAK1\/2 inhibitor, in patients with metastatic triple-negative breast cancer. NPJ Breast Cancer. 2018;4:10.","journal-title":"NPJ Breast Cancer"},{"issue":"1","key":"1116_CR83","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s12872-020-01391-7","volume":"20","author":"X Yang","year":"2020","unstructured":"Yang X, Jia J, Yu Z, Duanmu Z, He H, Chen S, et al. Inhibition of JAK2\/STAT3\/SOCS3 signaling attenuates atherosclerosis in rabbit. BMC Cardiovasc Disord. 2020;20(1):133.","journal-title":"BMC Cardiovasc Disord"},{"issue":"9","key":"1116_CR84","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.3390\/cancers12092669","volume":"12","author":"G Greenfield","year":"2020","unstructured":"Greenfield G, McPherson S, Smith J, Mead A, Harrison C, Mills K, et al. Modification of the histone landscape with JAK inhibition in myeloproliferative neoplasms. Cancers (Basel). 2020;12(9):2669.","journal-title":"Cancers (Basel)."},{"issue":"1","key":"1116_CR85","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ccell.2017.11.009","volume":"33","author":"M Kleppe","year":"2018","unstructured":"Kleppe M, Koche R, Zou L, van Galen P, Hill CE, Dong L, et al. Dual targeting of oncogenic activation and inflammatory signaling increases therapeutic efficacy in myeloproliferative neoplasms. Cancer Cell. 2018;33(1):29-43.e7.","journal-title":"Cancer Cell"},{"issue":"7","key":"1116_CR86","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1093\/carcin\/bgt070","volume":"34","author":"CQ Chen","year":"2013","unstructured":"Chen CQ, Yu K, Yan QX, Xing CY, Chen Y, Yan Z, et al. Pure curcumin increases the expression of SOCS1 and SOCS3 in myeloproliferative neoplasms through suppressing class I histone deacetylases. Carcinogenesis. 2013;34(7):1442\u20139.","journal-title":"Carcinogenesis"},{"issue":"3","key":"1116_CR87","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.exphem.2012.10.012","volume":"41","author":"SM Gao","year":"2013","unstructured":"Gao SM, Chen CQ, Wang LY, Hong LL, Wu JB, Dong PH, et al. Histone deacetylases inhibitor sodium butyrate inhibits JAK2\/STAT signaling through upregulation of SOCS1 and SOCS3 mediated by HDAC8 inhibition in myeloproliferative neoplasms. Exp Hematol. 2013;41(3):261-70 e4.","journal-title":"Exp Hematol."},{"issue":"16","key":"1116_CR88","doi-asserted-by":"publisher","first-page":"3779","DOI":"10.1182\/blood-2011-02-336743","volume":"119","author":"H Akada","year":"2012","unstructured":"Akada H, Akada S, Gajra A, Bair A, Graziano S, Hutchison RE, et al. Efficacy of vorinostat in a murine model of polycythemia vera. Blood. 2012;119(16):3779\u201389.","journal-title":"Blood"},{"issue":"15","key":"1116_CR89","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1182\/blood-2016-06-724658","volume":"129","author":"Y Nakata","year":"2017","unstructured":"Nakata Y, Ueda T, Nagamachi A, Yamasaki N, Ikeda KI, Sera Y, et al. Acquired expression of Cbl(Q367P) in mice induces dysplastic myelopoiesis mimicking chronic myelomonocytic leukemia. Blood. 2017;129(15):2148\u201360.","journal-title":"Blood"},{"issue":"43","key":"1116_CR90","doi-asserted-by":"publisher","first-page":"13342","DOI":"10.1073\/pnas.1507599112","volume":"112","author":"HH Zhu","year":"2015","unstructured":"Zhu HH, Luo X, Zhang K, Cui J, Zhao H, Ji Z, et al. Shp2 and Pten have antagonistic roles in myeloproliferation but cooperate to promote erythropoiesis in mammals. Proc Natl Acad Sci USA. 2015;112(43):13342\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"28","key":"1116_CR91","doi-asserted-by":"publisher","first-page":"5627","DOI":"10.1038\/s41388-019-0813-7","volume":"38","author":"J Stetka","year":"2019","unstructured":"Stetka J, Vyhlidalova P, Lanikova L, Koralkova P, Gursky J, Hlusi A, et al. Addiction to DUSP1 protects JAK2V617F-driven polycythemia vera progenitors against inflammatory stress and DNA damage, allowing chronic proliferation. Oncogene. 2019;38(28):5627\u201342.","journal-title":"Oncogene"},{"issue":"7728","key":"1116_CR92","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/s41586-018-0623-z","volume":"562","author":"JW Tyner","year":"2018","unstructured":"Tyner JW, Tognon CE, Bottomly D, Wilmot B, Kurtz SE, Savage SL, et al. Functional genomic landscape of acute myeloid leukaemia. Nature. 2018;562(7728):526\u201331.","journal-title":"Nature"},{"issue":"6","key":"1116_CR93","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1182\/blood-2017-02-769869","volume":"130","author":"F Zink","year":"2017","unstructured":"Zink F, Stacey SN, Norddahl GL, Frigge ML, Magnusson OT, Jonsdottir I, et al. Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly. Blood. 2017;130(6):742\u201352.","journal-title":"Blood"},{"issue":"2","key":"1116_CR94","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/leu.2013.336","volume":"28","author":"T Haferlach","year":"2014","unstructured":"Haferlach T, Nagata Y, Grossmann V, Okuno Y, Bacher U, Nagae G, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia. 2014;28(2):241\u20137.","journal-title":"Leukemia"},{"key":"1116_CR95","doi-asserted-by":"crossref","unstructured":"Williams N, Lee J, Moore L, Baxter EJ, Hewinson J, Dawson KJ, et al. Phylogenetic reconstruction of myeloproliferative neoplasm reveals very early origins and lifelong evolution. bioRxiv. 2020:2020.11.09.374710.","DOI":"10.1101\/2020.11.09.374710"},{"issue":"6","key":"1116_CR96","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1038\/leu.2010.69","volume":"24","author":"A Tefferi","year":"2010","unstructured":"Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia. 2010;24(6):1128\u201338.","journal-title":"Leukemia"},{"key":"1116_CR97","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41375-018-0159-0","volume":"33","author":"I Triviai","year":"2018","unstructured":"Triviai I, Zeschke S, Rentel J, Spanakis M, Scherer T, Gabdoulline R, et al. ASXL1\/EZH2 mutations promote clonal expansion of neoplastic HSC and impair erythropoiesis in PMF. Leukemia. 2018;33:99\u2013109.","journal-title":"Leukemia"},{"issue":"9","key":"1116_CR98","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1038\/leu.2013.119","volume":"27","author":"AM Vannucchi","year":"2013","unstructured":"Vannucchi AM, Lasho TL, Guglielmelli P, Biamonte F, Pardanani A, Pereira A, et al. Mutations and prognosis in primary myelofibrosis. Leukemia. 2013;27(9):1861\u20139.","journal-title":"Leukemia"},{"issue":"14","key":"1116_CR99","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1182\/blood-2013-11-537167","volume":"123","author":"P Lundberg","year":"2014","unstructured":"Lundberg P, Karow A, Nienhold R, Looser R, Hao-Shen H, Nissen I, et al. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood. 2014;123(14):2220\u20138.","journal-title":"Blood"},{"issue":"5","key":"1116_CR100","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1182\/bloodadvances.2020003444","volume":"5","author":"D Luque Paz","year":"2021","unstructured":"Luque Paz D, Riou J, Verger E, Cassinat B, Chauveau A, Ianotto JC, et al. Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM study. Blood Adv. 2021;5(5):1442\u201351.","journal-title":"Blood Adv"},{"issue":"7","key":"1116_CR101","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1038\/s41375-018-0107-z","volume":"32","author":"A Tefferi","year":"2018","unstructured":"Tefferi A, Guglielmelli P, Nicolosi M, Mannelli F, Mudireddy M, Bartalucci N, et al. GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis. Leukemia. 2018;32(7):1631\u201342.","journal-title":"Leukemia"},{"issue":"9","key":"1116_CR102","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1038\/leu.2014.76","volume":"28","author":"P Guglielmelli","year":"2014","unstructured":"Guglielmelli P, Lasho TL, Rotunno G, Score J, Mannarelli C, Pancrazzi A, et al. The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients. Leukemia. 2014;28(9):1804\u201310.","journal-title":"Leukemia"},{"issue":"17","key":"1116_CR103","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1200\/JCO.2018.78.9867","volume":"36","author":"A Tefferi","year":"2018","unstructured":"Tefferi A, Guglielmelli P, Lasho TL, Gangat N, Ketterling RP, Pardanani A, et al. MIPSS70+ version 2.0: mutation and karyotype-enhanced international prognostic scoring system for primary myelofibrosis. J Clin Oncol. 2018;36(17):1769\u201370.","journal-title":"J Clin Oncol."},{"issue":"7834","key":"1116_CR104","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s41586-020-2864-x","volume":"587","author":"LA Miles","year":"2020","unstructured":"Miles LA, Bowman RL, Merlinsky TR, Csete IS, Ooi AT, Durruthy-Durruthy R, et al. Single-cell mutation analysis of clonal evolution in myeloid malignancies. Nature. 2020;587(7834):477\u201382.","journal-title":"Nature"},{"issue":"8","key":"1116_CR105","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.3390\/cancers12082291","volume":"12","author":"K Geissler","year":"2020","unstructured":"Geissler K, Gisslinger B, Jager E, Jager R, Schiefer AI, Bogner E, et al. Myelomonocytic skewing in vitro discriminates subgroups of patients with myelofibrosis with a different phenotype, a different mutational profile and different prognosis. Cancers (Basel). 2020;12(8):2291.","journal-title":"Cancers (Basel)"},{"issue":"4","key":"1116_CR106","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1038\/leu.2014.289","volume":"29","author":"EK Engle","year":"2015","unstructured":"Engle EK, Fisher DA, Miller CA, McLellan MD, Fulton RS, Moore DM, et al. Clonal evolution revealed by whole genome sequencing in a case of primary myelofibrosis transformed to secondary acute myeloid leukemia. Leukemia. 2015;29(4):869\u201376.","journal-title":"Leukemia"},{"issue":"9","key":"1116_CR107","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1182\/blood-2017-05-783225","volume":"130","author":"KJ Newberry","year":"2017","unstructured":"Newberry KJ, Patel K, Masarova L, Luthra R, Manshouri T, Jabbour E, et al. Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation. Blood. 2017;130(9):1125\u201331.","journal-title":"Blood"},{"issue":"7","key":"1116_CR108","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1056\/NEJMoa1412098","volume":"372","author":"CA Ortmann","year":"2015","unstructured":"Ortmann CA, Kent DG, Nangalia J, Silber Y, Wedge DC, Grinfeld J, et al. Effect of mutation order on myeloproliferative neoplasms. N Engl J Med. 2015;372(7):601\u201312.","journal-title":"N Engl J Med"},{"issue":"11","key":"1116_CR109","doi-asserted-by":"publisher","first-page":"e438","DOI":"10.3324\/haematol.2015.129510","volume":"100","author":"J Nangalia","year":"2015","unstructured":"Nangalia J, Nice FL, Wedge DC, Godfrey AL, Grinfeld J, Thakker C, et al. DNMT3A mutations occur early or late in patients with myeloproliferative neoplasms and mutation order influences phenotype. Haematologica. 2015;100(11):e438\u201342.","journal-title":"Haematologica"},{"issue":"1","key":"1116_CR110","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ccr.2011.06.001","volume":"20","author":"K Moran-Crusio","year":"2011","unstructured":"Moran-Crusio K, Reavie L, Shih A, Abdel-Wahab O, Ndiaye-Lobry D, Lobry C, et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell. 2011;20(1):11\u201324.","journal-title":"Cancer Cell"},{"issue":"2","key":"1116_CR111","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1182\/blood-2014-04-555508","volume":"125","author":"T Kameda","year":"2015","unstructured":"Kameda T, Shide K, Yamaji T, Kamiunten A, Sekine M, Taniguchi Y, et al. Loss of TET2 has dual roles in murine myeloproliferative neoplasms: disease sustainer and disease accelerator. Blood. 2015;125(2):304\u201315.","journal-title":"Blood"},{"issue":"1","key":"1116_CR112","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/ng.1009","volume":"44","author":"GA Challen","year":"2011","unstructured":"Challen GA, Sun D, Jeong M, Luo M, Jelinek J, Berg JS, et al. Dnmt3a is essential for hematopoietic stem cell differentiation. Nat Genet. 2011;44(1):23\u201331.","journal-title":"Nat Genet"},{"issue":"1","key":"1116_CR113","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.celrep.2018.03.025","volume":"23","author":"M Jeong","year":"2018","unstructured":"Jeong M, Park HJ, Celik H, Ostrander EL, Reyes JM, Guzman A, et al. Loss of Dnmt3a immortalizes hematopoietic stem cells in vivo. Cell Rep. 2018;23(1):1\u201310.","journal-title":"Cell Rep"},{"issue":"8","key":"1116_CR114","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1084\/jem.20151136","volume":"213","author":"T Shimizu","year":"2016","unstructured":"Shimizu T, Kubovcakova L, Nienhold R, Zmajkovic J, Meyer SC, Hao-Shen H, et al. Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis. J Exp Med. 2016;213(8):1479\u201396.","journal-title":"J Exp Med"},{"issue":"1","key":"1116_CR115","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1182\/blood-2006-12-062125","volume":"110","author":"A Theocharides","year":"2007","unstructured":"Theocharides A, Boissinot M, Girodon F, Garand R, Teo SS, Lippert E, et al. Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood. 2007;110(1):375\u20139.","journal-title":"Blood"},{"issue":"7689","key":"1116_CR116","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/nature25022","volume":"553","author":"E Laurenti","year":"2018","unstructured":"Laurenti E, Gottgens B. From haematopoietic stem cells to complex differentiation landscapes. Nature. 2018;553(7689):418\u201326.","journal-title":"Nature"},{"issue":"7831","key":"1116_CR117","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1038\/s41586-020-2819-2","volume":"586","author":"AG Bick","year":"2020","unstructured":"Bick AG, Weinstock JS, Nandakumar SK, Fulco CP, Bao EL, Zekavat SM, et al. Inherited causes of clonal haematopoiesis in 97,691 whole genomes. Nature. 2020;586(7831):763\u20138.","journal-title":"Nature"},{"issue":"9","key":"1116_CR118","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1182\/blood-2006-04-017392","volume":"108","author":"T Ishii","year":"2006","unstructured":"Ishii T, Bruno E, Hoffman R, Xu M. Involvement of various hematopoietic-cell lineages by the JAK2V617F mutation in polycythemia vera. Blood. 2006;108(9):3128\u201334.","journal-title":"Blood"},{"key":"1116_CR119","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.leukres.2016.06.009","volume":"48","author":"A Angona","year":"2016","unstructured":"Angona A, Alvarez-Larran A, Bellosillo B, Longaron R, Camacho L, Fernandez-Rodriguez MC, et al. Characterization of CD34+ hematopoietic progenitor cells in JAK2V617F and CALR-mutated myeloproliferative neoplasms. Leuk Res. 2016;48:11\u20135.","journal-title":"Leuk Res"},{"issue":"7","key":"1116_CR120","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1038\/nm.4103","volume":"22","author":"A Reinisch","year":"2016","unstructured":"Reinisch A, Thomas D, Corces MR, Zhang X, Gratzinger D, Hong WJ, et al. A humanized bone marrow ossicle xenotransplantation model enables improved engraftment of healthy and leukemic human hematopoietic cells. Nat Med. 2016;22(7):812\u201321.","journal-title":"Nat Med"},{"issue":"1","key":"1116_CR121","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1182\/blood-2012-01-402396","volume":"120","author":"A Mullally","year":"2012","unstructured":"Mullally A, Poveromo L, Schneider RK, Al-Shahrour F, Lane SW, Ebert BL. Distinct roles for long-term hematopoietic stem cells and erythroid precursor cells in a murine model of Jak2V617F-mediated polycythemia vera. Blood. 2012;120(1):166\u201372.","journal-title":"Blood"},{"issue":"7470","key":"1116_CR122","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/nature12495","volume":"502","author":"A Sanjuan-Pla","year":"2013","unstructured":"Sanjuan-Pla A, Macaulay IC, Jensen CT, Woll PS, Luis TC, Mead A, et al. Platelet-biased stem cells reside at the apex of the haematopoietic stem-cell hierarchy. Nature. 2013;502(7470):232\u20136.","journal-title":"Nature"},{"issue":"7690","key":"1116_CR123","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/nature25455","volume":"554","author":"J Carrelha","year":"2018","unstructured":"Carrelha J, Meng Y, Kettyle LM, Luis TC, Norfo R, Alcolea V, et al. Hierarchically related lineage-restricted fates of multipotent haematopoietic stem cells. Nature. 2018;554(7690):106\u201311.","journal-title":"Nature"},{"issue":"3","key":"1116_CR124","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.molcel.2020.04.008","volume":"78","author":"B Psaila","year":"2020","unstructured":"Psaila B, Wang G, Rodriguez-Meira A, Li R, Heuston EF, Murphy L, et al. Single-cell analyses reveal megakaryocyte-biased hematopoiesis in myelofibrosis and identify mutant clone-specific targets. Mol Cell. 2020;78(3):477-92 e8.","journal-title":"Mol Cell."},{"issue":"3","key":"1116_CR125","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.stem.2021.01.018","volume":"28","author":"J Tong","year":"2021","unstructured":"Tong J, Sun T, Ma S, Zhao Y, Ju M, Gao Y, et al. Hematopoietic stem cell heterogeneity is linked to the initiation and therapeutic response of myeloproliferative neoplasms. Cell Stem Cell. 2021;28(3):502-13 e6.","journal-title":"Cell Stem Cell."},{"issue":"6","key":"1116_CR126","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.stem.2017.03.008","volume":"20","author":"RK Schneider","year":"2017","unstructured":"Schneider RK, Mullally A, Dugourd A, Peisker F, Hoogenboezem R, Van Strien PMH, et al. Gli1(+) mesenchymal stromal cells are a key driver of bone marrow fibrosis and an important cellular therapeutic target. Cell Stem Cell. 2017;20(6):785-800 e8.","journal-title":"Cell Stem Cell."},{"issue":"6","key":"1116_CR127","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/ncb3530","volume":"19","author":"M Decker","year":"2017","unstructured":"Decker M, Martinez-Morentin L, Wang G, Lee Y, Liu Q, Leslie J, et al. Leptin-receptor-expressing bone marrow stromal cells are myofibroblasts in primary myelofibrosis. Nat Cell Biol. 2017;19(6):677\u201388.","journal-title":"Nat Cell Biol"},{"issue":"4","key":"1116_CR128","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.stem.2020.11.004","volume":"28","author":"NB Leimkuhler","year":"2021","unstructured":"Leimkuhler NB, Gleitz HFE, Ronghui L, Snoeren IAM, Fuchs SNR, Nagai JS, et al. Heterogeneous bone-marrow stromal progenitors drive myelofibrosis via a druggable alarmin axis. Cell Stem Cell. 2021;28(4):637-52 e8.","journal-title":"Cell Stem Cell."},{"issue":"1","key":"1116_CR129","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.ajhg.2017.05.013","volume":"101","author":"R Acuna-Hidalgo","year":"2017","unstructured":"Acuna-Hidalgo R, Sengul H, Steehouwer M, van de Vorst M, Vermeulen SH, Kiemeney LALM, et al. Ultra-sensitive sequencing identifies high prevalence of clonal hematopoiesis-associated mutations throughout adult life. Am J Hum Genet. 2017;101(1):50\u201364.","journal-title":"Am J Hum Genet"},{"issue":"4","key":"1116_CR130","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2017-02-735290","volume":"130","author":"LA Godley","year":"2017","unstructured":"Godley LA, Shimamura A. Genetic predisposition to hematologic malignancies: management and surveillance. Blood. 2017;130(4):424\u201332.","journal-title":"Blood"},{"issue":"9","key":"1116_CR131","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1182\/blood-2018-06-858597","volume":"132","author":"A Sud","year":"2018","unstructured":"Sud A, Chattopadhyay S, Thomsen H, Sundquist K, Sundquist J, Houlston RS, et al. Familial risks of acute myeloid leukemia, myelodysplastic syndromes, and myeloproliferative neoplasms. Blood. 2018;132(9):973\u20136.","journal-title":"Blood"},{"issue":"35","key":"1116_CR132","doi-asserted-by":"publisher","first-page":"5630","DOI":"10.1200\/JCO.2007.12.6896","volume":"25","author":"E Rumi","year":"2007","unstructured":"Rumi E, Passamonti F, Della Porta MG, Elena C, Arcaini L, Vanelli L, et al. Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation. J Clin Oncol. 2007;25(35):5630\u20135.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1116_CR133","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1111\/j.1365-2141.2008.07430.x","volume":"144","author":"HA el El-Harith","year":"2009","unstructured":"el El-Harith HA, Roesl C, Ballmaier M, Germeshausen M, Frye-Boukhriss H, von Neuhoff N, et al. Familial thrombocytosis caused by the novel germ-line mutation p.Pro106Leu in the MPL gene. Br J Haematol. 2009;144(2):185\u201394.","journal-title":"Br J Haematol."},{"issue":"11","key":"1116_CR134","doi-asserted-by":"publisher","first-page":"4198","DOI":"10.1182\/blood-2003-10-3471","volume":"103","author":"J Ding","year":"2004","unstructured":"Ding J, Komatsu H, Wakita A, Kato-Uranishi M, Ito M, Satoh A, et al. Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin. Blood. 2004;103(11):4198\u2013200.","journal-title":"Blood"},{"issue":"4","key":"1116_CR135","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/ng.334","volume":"41","author":"AV Jones","year":"2009","unstructured":"Jones AV, Chase A, Silver RT, Oscier D, Zoi K, Wang YL, et al. JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nat Genet. 2009;41(4):446\u20139.","journal-title":"Nat Genet"},{"issue":"7831","key":"1116_CR136","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/s41586-020-2786-7","volume":"586","author":"EL Bao","year":"2020","unstructured":"Bao EL, Nandakumar SK, Liao X, Bick AG, Karjalainen J, Tabaka M, et al. Inherited myeloproliferative neoplasm risk affects haematopoietic stem cells. Nature. 2020;586(7831):769\u201375.","journal-title":"Nature"},{"issue":"24","key":"1116_CR137","doi-asserted-by":"publisher","first-page":"38693","DOI":"10.18632\/oncotarget.16309","volume":"8","author":"H Li","year":"2017","unstructured":"Li H, Xu Y, Mei H, Peng L, Li X, Tang J. The TERT rs2736100 polymorphism increases cancer risk: a meta-analysis. Oncotarget. 2017;8(24):38693\u2013705.","journal-title":"Oncotarget"},{"issue":"1","key":"1116_CR138","doi-asserted-by":"publisher","first-page":"e327","DOI":"10.1097\/HS9.0000000000000327","volume":"4","author":"AS Duncombe","year":"2020","unstructured":"Duncombe AS, Anderson LA, James G, de Vocht F, Fritschi L, Mesa R, et al. Modifiable lifestyle and medical risk factors associated with myeloproliferative neoplasms. Hemasphere. 2020;4(1):e327.","journal-title":"Hemasphere."},{"issue":"7","key":"1116_CR139","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.3324\/haematol.2009.014407","volume":"95","author":"BL Stein","year":"2010","unstructured":"Stein BL, Williams DM, Wang NY, Rogers O, Isaacs MA, Pemmaraju N, et al. Sex differences in the JAK2 V617F allele burden in chronic myeloproliferative disorders. Haematologica. 2010;95(7):1090\u20137.","journal-title":"Haematologica"},{"issue":"14","key":"1116_CR140","doi-asserted-by":"publisher","first-page":"13364","DOI":"10.1074\/jbc.M407326200","volume":"280","author":"V Moucadel","year":"2005","unstructured":"Moucadel V, Constantinescu SN. Differential STAT5 signaling by ligand-dependent and constitutively active cytokine receptors. J Biol Chem. 2005;280(14):13364\u201373.","journal-title":"J Biol Chem"},{"issue":"18","key":"1116_CR141","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1182\/blood-2017-10-810622","volume":"131","author":"JC Peeken","year":"2018","unstructured":"Peeken JC, Jutzi JS, Wehrle J, Koellerer C, Staehle HF, Becker H, et al. Epigenetic regulation of NFE2 overexpression in myeloproliferative neoplasms. Blood. 2018;131(18):2065\u201373.","journal-title":"Blood"},{"issue":"2","key":"1116_CR142","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.ccr.2010.12.020","volume":"19","author":"F Liu","year":"2011","unstructured":"Liu F, Zhao X, Perna F, Wang L, Koppikar P, Abdel-Wahab O, et al. JAK2V617F-mediated phosphorylation of PRMT5 downregulates its methyltransferase activity and promotes myeloproliferation. Cancer Cell. 2011;19(2):283\u201394.","journal-title":"Cancer Cell"},{"issue":"7265","key":"1116_CR143","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1038\/nature08448","volume":"461","author":"MA Dawson","year":"2009","unstructured":"Dawson MA, Bannister AJ, G\u00f6ttgens B, Foster SD, Bartke T, Green AR, et al. JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin. Nature. 2009;461(7265):819\u201322.","journal-title":"Nature"},{"issue":"8","key":"1116_CR144","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1084\/jem.20151121","volume":"213","author":"G Sashida","year":"2016","unstructured":"Sashida G, Wang C, Tomioka T, Oshima M, Aoyama K, Kanai A, et al. The loss of Ezh2 drives the pathogenesis of myelofibrosis and sensitizes tumor-initiating cells to bromodomain inhibition. J Exp Med. 2016;213(8):1459\u201377.","journal-title":"J Exp Med"},{"issue":"9","key":"1116_CR145","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.3324\/haematol.2013.084160","volume":"98","author":"C P\u00e9rez","year":"2013","unstructured":"P\u00e9rez C, Pascual M, Mart\u00edn-Subero JI, Bellosillo B, Segura V, Delabesse E, et al. Aberrant DNA methylation profile of chronic and transformed classic Philadelphia-negative myeloproliferative neoplasms. Haematologica. 2013;98(9):1414\u201320.","journal-title":"Haematologica"},{"key":"1116_CR146","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.exphem.2019.09.025","volume":"79","author":"S McPherson","year":"2019","unstructured":"McPherson S, Greenfield G, Andersen C, Grinfeld J, Hasselbalch H, Nangalia J, et al. Methylation age as a correlate for allele burden, disease status and clinical response in myeloproliferative neoplasm patients treated with Vorinostat. Exp Hematol. 2019;79:26\u201334.","journal-title":"Exp Hematol"},{"issue":"12","key":"1116_CR147","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1007\/s00277-016-2812-x","volume":"95","author":"C Augello","year":"2016","unstructured":"Augello C, Cattaneo D, Bucelli C, Terrasi A, Fermo E, Martinelli I, et al. CD18 promoter methylation is associated with a higher risk of thrombotic complications in primary myelofibrosis. Ann Hematol. 2016;95(12):1965\u20139.","journal-title":"Ann Hematol"},{"issue":"9","key":"1116_CR148","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1038\/leu.2013.120","volume":"27","author":"J Broseus","year":"2013","unstructured":"Broseus J, Alpermann T, Wulfert M, Florensa Brichs L, Jeromin S, Lippert E, et al. Age, JAK2(V617F) and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis. Leukemia. 2013;27(9):1826\u201331.","journal-title":"Leukemia"},{"issue":"20","key":"1116_CR149","doi-asserted-by":"publisher","first-page":"5246","DOI":"10.1182\/bloodadvances.2020002119","volume":"4","author":"JO Mascarenhas","year":"2020","unstructured":"Mascarenhas JO, Rampal RK, Kosiorek HE, Bhave R, Hexner E, Wang ES, et al. Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase. Blood Adv. 2020;4(20):5246\u201356.","journal-title":"Blood Adv"},{"issue":"1","key":"1116_CR150","doi-asserted-by":"publisher","first-page":"e516","DOI":"10.1097\/HS9.0000000000000516","volume":"5","author":"S Brkic","year":"2021","unstructured":"Brkic S, Meyer SC. Challenges and perspectives for therapeutic targeting of myeloproliferative neoplasms. Hemasphere. 2021;5(1):e516.","journal-title":"Hemasphere."},{"issue":"15","key":"1116_CR151","doi-asserted-by":"publisher","first-page":"3677","DOI":"10.1182\/bloodadvances.2020002175","volume":"4","author":"G Coltro","year":"2020","unstructured":"Coltro G, Rotunno G, Mannelli L, Mannarelli C, Fiaccabrino S, Romagnoli S, et al. RAS\/CBL mutations predict resistance to JAK inhibitors in myelofibrosis and are associated with poor prognostic features. Blood Adv. 2020;4(15):3677\u201387.","journal-title":"Blood Adv"},{"issue":"1","key":"1116_CR152","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41467-019-13892-x","volume":"11","author":"E Mylonas","year":"2020","unstructured":"Mylonas E, Yoshida K, Frick M, Hoyer K, Christen F, Kaeda J, et al. Single-cell analysis based dissection of clonality in myelofibrosis. Nat Commun. 2020;11(1):73.","journal-title":"Nat Commun"},{"issue":"4","key":"1116_CR153","doi-asserted-by":"publisher","first-page":"e165","DOI":"10.1016\/S2352-3026(17)30030-3","volume":"4","author":"L Masarova","year":"2017","unstructured":"Masarova L, Patel KP, Newberry KJ, Cortes J, Borthakur G, Konopleva M, et al. Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial. Lancet Haematol. 2017;4(4):e165\u201375.","journal-title":"Lancet Haematol"},{"issue":"16","key":"1116_CR154","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1182\/blood.2020005563","volume":"137","author":"TN Rao","year":"2021","unstructured":"Rao TN, Hansen N, Stetka J, Luque Paz D, Kalmer M, Hilfiker J, et al. JAK2-V617F and interferon-alpha induce megakaryocyte-biased stem cells characterized by decreased long-term functionality. Blood. 2021;137(16):2139\u201351.","journal-title":"Blood"},{"issue":"1","key":"1116_CR155","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s13045-020-00995-y","volume":"13","author":"S Venugopal","year":"2020","unstructured":"Venugopal S, Mascarenhas J. Novel therapeutics in myeloproliferative neoplasms. J Hematol Oncol. 2020;13(1):162.","journal-title":"J Hematol Oncol"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-021-01116-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-021-01116-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-021-01116-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T09:09:24Z","timestamp":1625044164000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-021-01116-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,30]]},"references-count":155,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1116"],"URL":"https:\/\/doi.org\/10.1186\/s13045-021-01116-z","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,30]]},"assertion":[{"value":"21 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"GG and KM have no competing interests to declare. MFM has undertaken advisory board work and received speaker fees from Novartis and undertaken advisory board work for Celgene, Incyte and AbbVie.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"103"}}